Resources from the same session
4197 - A phase 1b/2 study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results
Presenter: Ezra Cohen
Session: Proffered paper session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
4263 - M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-_, in patients (pts) with advanced SCCHN: results from a phase 1 cohort
Presenter: Byoung Chul Cho
Session: Proffered paper session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
5398 - A phase II window of opportunity study of preoperative olaparib (O) with cisplatin (C) or durvalumab (D) or olaparib alone in in patients with operable squamous cell head and neck carcinoma (HNSCC) (OPHELIA)
Presenter: Amanda Psyrri
Session: Proffered paper session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
5432 - Preliminary results from a phase 2 trial of tipifarnib in Squamous Cell Carcinomas (SCCs) with HRAS mutations.
Presenter: Alan Ho
Session: Proffered paper session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
Proffered paper session - Head and neck cancer - Invited Discussant 1044O and 1048O
Presenter: Sandrine Faivre
Session: Proffered paper session - Head and neck cancer
Resources:
Slides
Webcast